99566-27-5

Basic information

• Product Name: NEUROPEPTIDE FF
• Synonyms: PHE-LEU-PHE-GLN-PRO-GLN-ARG-PHE AMIDE;PHE-LEU-PHE-GLN-PRO-GLN-ARG-PHE-NH2;NPFF;NEUROPEPTIDE FF;H-PHE-LEU-PHE-GLN-PRO-GLN-ARG-PHE-NH2;F-8-F-NH2;ninamide;phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylala
• CAS NO: 99566-27-5
• Molecular Formula: C54H76N14O10
• Molecular Weight: 1081.27
• Product Categories: Peptide
• Mol File: 99566-27-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.38 g/cm³
• Refractive Index: 1.656
• Storage Temp.: −20°C
• Water Solubility: Soluble to 0.50 mg/ml in water.
• CAS DataBase Reference: NEUROPEPTIDE FF(CAS DataBase Reference)
• NIST Chemistry Reference: NEUROPEPTIDE FF(99566-27-5)
• EPA Substance Registry System: NEUROPEPTIDE FF(99566-27-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 99566-27-5(Hazardous Substances Data)

Usage

Description

Neuropeptide FF (NPFF) is a peptide expressed in the brain and spinal cord that shares a precursor protein with neuropeptide AF. NPFF is expressed primarily in the posterior pituitary, hypothalamus, and medulla. It is an agonist at NPFF1 and NPFF2 receptors (Kis = 2.82 and 0.21 nM, respectively, for human recombinant receptors) that inhibits forskolin-induced cAMP production in CHO cells (EC50s = 236 and 2.3 nM, respectively). NPFF activates parvocellular neurons in the paraventricular nucleus (PVN) of the hypothalamus to stimulate oxytocin release from their projections in the brain stem, thereby regulating baroreflex control of heart rate. However, it inhibits magnocellular PVN neurons by enhancing GABAergic input. It is also found in plasma and exogenous administration briefly increases mean arterial pressure (MAP) by 40 mm Hg in rats, an effect that is only partially blocked by the norepinephrine competitor guanethidine and the α1-adrenergic receptor antagonist prazosin . NPFF has anti-opioid effects in rodent models, inhibiting morphine-induced analgesia and inducing abstinence in morphine-tolerant rats. It also inhibits acquisition of conditioned place preference to cocaine in rats when administered at doses of 10 and 20 nmol.

Uses

Endogenous antiopioid peptide and agonist at NPFF1 and NPFF2 receptors (Ki values are 2.82 and 0.21 nM respectively). Exhibits anorexigenic effects.

InChI:InChI=1/C54H76N14O10/c1-32(2)28-41(66-47(72)36(55)29-33-14-6-3-7-15-33)50(75)67-42(31-35-18-10-5-11-19-35)51(76)64-39(23-25-45(57)70)53(78)68-27-13-21-43(68)52(77)63-38(22-24-44(56)69)49(74)62-37(20-12-26-61-54(59)60)48(73)65-40(46(58)71)30-34-16-8-4-9-17-34/h3-11,14-19,32,36-43H,12-13,20-31,55H2,1-2H3,(H2,56,69)(H2,57,70)(H2,58,71)(H,62,74)(H,63,77)(H,64,76)(H,65,73)(H,66,72)(H,67,75)(H4,59,60,61)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 13726-85-7 Boc-Gln-OH 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 13836-37-8 Boc-Arg(Tos)-OH 
• 35661-60-0 Fmoc-Leu-OH 
• 71989-31-6 Fmoc-Pro-OH 
• 35661-40-6 N-Fmoc L-Phe 
• 71989-20-3 N₂-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-glutamine 
• 91000-69-0 Fmoc-L-Arg-OH 

Relevant articles and documents

Pressor and tachycardic responses to intrathecal administration of neuropeptide FF in anesthetized rats

Neuropeptide FF (NPFF) belongs to a neuropeptide family including two precursors (pro-NPFFA and pro-NPFFB) and two receptors (NPFF1 and NPFF2). NPFF and NPFF receptor mRNAs have been reported to be highly expressed and localized in the rat and human spinal cord. In the present study, the i.t. action of NPFF system on blood pressure and heart rate were examined using NPFF and two related agonists, NPVF and dNPA, which exhibit highest selectivities for NPFF1 and NPFF2 receptors, respectively. In urethane-anesthetized rats, NPFF and related peptides (5-40 nmol, i.t.) produced significant pressor and tachycardic responses at the spinal cord level. These effects were dose-dependent and similar with respect to time-course for the three peptides. Furthermore, i.t. injection of RF9 (20 nmol), a selective NPFF antagonist, significantly antagonized the cardiovascular responses to 20 nmol NPFF and related peptides (i.t.). Moreover, pretreatment of the rats with α-adrenoceptor antagonist phentolamine (1 mg/kg, i.v.) significantly reduced the pressor effects of NPFF. Nevertheless, pretreatment with muscarinic receptor and adrenoceptor antagonists (i.v.) could block the tachycardic effects induced by NPFF. Collectively, our results suggested that i.t. administration of NPFF and related peptides increased MAP and HR which were possibly mediated by the activation of both NPFF1 and NPFF2 receptors in the rat spinal cord. In addition, our results showed that the muscarinic receptor and adrenoceptor participated in the tachycardic response to i.t. NPFF, while α-adrenoceptor played an important role in the regulation of pressor effect of NPFF.